At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
olaratumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted May 8, 2009·Updated Dec 27, 2017
In Brief
A Phase 2 clinical trial evaluating olaratumab and ramucirumab for Adult Glioblastoma Multiforme. Completed, enrolled 80 participants across 11 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as ramucirumab and anti-PDGFR alpha monoclonal antibody IMC-3G3 (Olaratumab), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well ramucirumab or anti-PDGFR alpha monoclonal antibody IMC-3G3 works in treating patients with recurrent glioblastoma multiforme.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Glioblastoma Multiforme
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Eli Lilly and Company
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJul 2010
Primary CompletionJun 2012
Study CompletionMar 2014
TodayJul 2026
First PostedMay 8, 2009
Enrollment StartJul 1, 2010
Primary CompletionJun 22, 2012
Study CompletionMar 4, 2014
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 17.2 years ago
Interventions
olaratumabbiological
Given IV
ramucirumabbiological
Given IV